The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Alnuctamab: improved route of administration and optimized dose level & dosing schedule
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the advantages of alnuctamab, a BCMAxCD3 bispecific antibody, for the treatment of multiple myeloma. Dr Costa explains that whilst this agent used to be administered intravenously, it is now given subcutaneously, which has led to a decrease in the severity of cytokine release syndrome (CRS). In addition, the dose levels and schedule of this drug have been optimized, and whilst efficacy is similar to that of other bispecific antibodies, the duration of response appears very promising. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
